IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
View original at nasdaq.comIHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? Key Points iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
IHE's outsized recent gains are largely due to the success of GLP-1 weight-loss drugs, making it vulnerable to competition from lower-cost biosimilars.
60% confidenceThe Motley Fool has positions in and recommends AbbVie, Bristol Myers Squibb, and Eli Lilly, and recommends Johnson & Johnson.
60% confidenceThe Motley Fool Stock Advisor analyst team identified 10 best stocks to buy now, and iShares Global Healthcare ETF was not among them.
60% confidenceCory Renauer has no position in any of the stocks mentioned.
60% confidenceIXJ is less likely to underperform due to a single issue because of its exposure to insurance companies and medical technology manufacturers.
60% confidenceStock Advisor's total average return is 900%, compared to 207% for the S&P 500, as of July 18, 2026.
60% confidenceInvestors looking to diversify their holdings probably want to avoid the iShares U.S. Pharmaceuticals ETF because its benchmark index is heavily weighted toward Johnson & Johnson and Eli Lilly.
60% confidence
Data points we hold from this source
| Netflix Inc. · investment growth 1000 | 371842 USD |